Means and Methods for Treating Angiogenesis-Related Diseases
Endostatin is an antiangiogenic protein first discovered in Folkman's laboratory at Childrens Hospital, Harvard Medical School, and Boston. The antitumor properties of this pro-tein are well established. However, the amount of protein required for injection in pa-tients was beyond production feasibility due to the poor pharmacokinetics of endostatin mon-omer.
We have shown that the problem of poor pharmacokinetics can be solved by using the Fc domain of IgG being conjugated to en-dostatin, a component of all monoclonal anti-bodies approved for patients with a number of diseases including cancer. As a result of em-ploying Fc-endostatin, the half-life in mice was increased to 2 weeks instead of 2 hours for endostatin alone, consistent with pharmacoki-netics of monoclonal antibodies
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles

Using Electroencephalography to Improve Language Disorder Treatments
Researchers work towards an inexpensive and portable solution for treating aphasia Electroencephalography (EEG) may offer a more accessible alternative to functional magnetic resonance imaging (fMRI) for guiding transcranial direct current…

Measuring Life on Earth from Space: A Global Research Project
Measurements and data collected from space can be used to better understand life on Earth. An ambitious, multinational research project funded by NASA and co-led by UC Merced civil and…

Best Approach for Stroke in Medium-Sized Blood Vessels Identified
Calgary’s Stroke Program advancing science to improve care, treatment and outcomes for patients University of Calgary’s Hotchkiss Brain Institute researchers with the Calgary Stroke Program at Foothills Medical Centre revolutionized…